I am a chemical biologist focusing on drug discovery, with a particular interest in emerging drug modalities such as ADCs, PROTACs, and other conjugated therapeutic molecules. Although these platforms are still relatively novel, their PK/PD behavior is an active area of research. I am especially interested in how PK/PD data are analyzed, interpreted, and leveraged to optimize these therapeutics—so we can translate promising mechanisms into practical, effective treatments.